Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
The Buxton Helmsley Group (BHG) urges Assertio stockholders to vote against all director nominees at the upcoming annual meeting on May 23, 2024. BHG criticizes Assertio’s board for failing in oversight, inadequate disclosures, and poor strategic decisions, including a costly acquisition of Spectrum Pharmaceuticals. Analysts have dropped coverage of Assertio, citing a loss of faith in leadership. BHG proposes adding two new directors to bring better oversight and restore value for stockholders. The group also recommends strategic alternatives, including a possible sale to enhance operating profit.
Assertio Holdings, Inc. will present at the Citizens JMP Life Sciences Conference in New York City on May 13, 2024. Ajay Patel, Chief Financial Officer, will lead the presentation at 12:00 pm Eastern Time. Investors can request meetings with the Company through JMP representatives or contact Assertio investor relations. Presentation information will be available on the event day at https://investor.assertiotx.com. To listen to the webcast, connect to the website link 15 minutes before the live webcast.
Assertio Holdings, Inc. reported strong first-quarter financial results, with net product sales of $31.9 million. Rolvedon product sales increased, while Indocin sales decreased due to generic competition. The company's gross margin was 65%, SG&A expenses decreased, and adjusted EBITDA improved. Assertio generated $7.5 million in cash flow, ending the quarter with $80.7 million in cash and cash equivalents. The company reiterated its 2024 financial guidance of $110-125 million in net product sales and $20-30 million in adjusted EBITDA.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.